Renal cell carcinoma of the native kidney in a renal transplant recipient

Vikrampal Bhatti, Ananthalaxmi Vangapalli, Deepti Bhattacharya, Abhilash Koratala

ABSTRACT

Abstract is not required for Clinical Images
Renal cell carcinoma of the native kidney in a renal transplant recipient

Vikrampal Bhatti, Ananthalaxmi Vangapalli, Deepti Bhattacharya, Abhilash Koratala

CASE REPORT

A 73-year-old white male was seen for fever, back pain and dysuria of three-day duration. His past medical history was significant for end stage renal disease secondary to hypertensive nephropathy status post deceased donor kidney transplant ten years ago and multiple skin cancers status post resection. His maintenance immunosuppression included tacrolimus 3 mg twice a day, azathioprine 75 mg daily and prednisone 10 mg daily. He was treated with antibiotics for Urinary tract infection. Ultrasound of the transplanted kidney was normal and the serum creatinine was at baseline. However, native kidney ultrasound done because of the back pain showed ~6 cm mass in the right kidney (Figure 1A). He never had gross or microscopic hematuria. His symptoms improved but MRI scan of abdomen showed heterogeneous mass (5.2x5.1x4.8 cm) in the superior pole of the right kidney suggestive of renal cell carcinoma along with bony lesions suspicious for metastases. Also, there were multiple cysts in both native kidneys and he did not have cystic renal disease prior to transplant (Figure 1B–C). He developed acquired cystic renal disease of native kidneys which unfortunately, was never screened for.

DISCUSSION

The incidence of renal cell carcinoma is increased in kidney transplant recipients and, particularly those with acquired cystic disease of the kidneys [1]. Chronic renal failure (particularly in patients on maintenance dialysis) is frequently associated with the development of multiple and bilateral renal cysts [2, 3]. There is conflicting data on whether to screen patients with advanced kidney disease for acquired cystic disease and thereby early detection of premalignant or malignant lesions [4–6]. Current major guidelines do not recommend routine screening of average risk patients for renal cell carcinoma. The learning point from our case is that till we have detailed guidelines designed by the major international transplantation societies, it is prudent to screen transplant recipients with periodic ultrasound of the native kidneys (6 months to 1 year) irrespective of the presence or absence of microscopic hematuria. In fact, a Japanese study has shown that in dialysis patients with renal cell carcinoma, the survival rate in the group detected by screening was better than that in the group detected by symptoms [8]. If the ultrasound demonstrates cysts, a computed tomography (CT) scan with contrast or magnetic resonance imaging (MRI) scan...
without gadolinium may be performed at yearly intervals especially in patients with good life expectancy and those with larger lesions to screen for the possible development of malignancy [6, 9]. Urology consultation should be sought for patients with Bosniak class III and IV cysts, to discuss the surgical options including total nephrectomy or nephron-sparing (partial) nephrectomy.

CONCLUSION

Our case of renal cell carcinoma that developed in a renal transplant patient and acquired cystic disease of the native kidneys emphasizes the need for establishment of routine screening protocol in such patients.

Keywords: Acquired cystic renal disease, Renal cell carcinoma, Screening

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2017 Vikrampal Bhatti et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES


How to cite this article

Article ID: Z01201702CL10117VB

doi:10.5348/ijcri-201707-CL-10117

Author Contributions
Vikrampal Bhatti – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Ananthalaxmi Vangapalli – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Deepti Bhattacharya – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Abhilash Koratala – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.